Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows

  • Johnson & Johnson JNJ and AbbVie Inc ABBV announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL).
  • The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR and rituximab maintenance.
  • Median progression-free survival (PFS) was 80.6 months with ibrutinib combined with bendamustine-rituximab and rituximab maintenance.
  • That compared with 52.9 months for the chemotherapy regimen in the 523-patient trial.
  • MCL is a rare type of lymphoma with an incidence of around 1 case per 200,000 people a year.
  • The complete response rate was 65.5% in the ibrutinib group and 57.6% in the placebo.
  • There was no difference in overall survival (OS) between treatment groups. The patients in the study continue to be followed for longer-term OS.
  • Price Action: JNJ shares are up 0.65% at $177.57, and ABBV shares are down 0.36% at $146.64 during the market session on the last check Monday.

Posted In: BriefsBiotechLarge CapNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.